Effects of VLDL and remnant particles on platelets
- PMID: 16877877
- DOI: 10.1159/000093221
Effects of VLDL and remnant particles on platelets
Abstract
There is a considerable body of evidence supporting an association between hypertriglyceridaemia, a hypercoagulable state and atherothrombosis. A disorder of triglyceride metabolism is a key feature of the metabolic syndrome that increases risk of both ischaemic heart disease and type 2 diabetes approximately 3-fold. An increasing prevalence of obesity and metabolic syndrome is likely to contribute markedly to the prevalent ischaemic heart in the foreseeable future, and therefore it is crucial to understand mechanisms linking hypertriglyceridaemia and a hypercoagulable state. Activation of platelets and the coagulation cascade are intertwined. VLDL and remnant lipoprotein concentrations are often increased with the metabolic syndrome. These lipoproteins have the capacity to activate platelets and the coagulation pathway, and to support the assembly of the prothrombinase complex. VLDL also upregulates expression of the plasminogen activator inhibitor-1 gene and plasminogen activator inhibitor-1 antigen and activity, a process accompanied by platelet aggregation and clot formation. The surface membrane of activated platelets also supports the assembly and activity of the prothrombinase complex, resulting in further thrombin generation and amplification of the coagulation cascade. Fibrinolysis is also less efficient when thrombin is generated. Thrombin induces thrombin activatable fibrinolysis inhibitor. Thrombin activatable fibrinolysis inhibitor is a carboxypeptidase that cleaves the carboxylic lysine residues on fibrin, thereby abolishing the critical binding site for tPA-plasminogen decreasing plasmin formation. Thus the evidence is supportive of dysregulated coagulation, and impaired fibrinolysis with a predisposition to atherothrombosis, in conditions such as the metabolic syndrome, in which there are increased concentrations of VLDL and remnant lipoproteins. The purpose of this review is to describe the current evidence supporting a procoagulant state induced by VLDL and remnant lipoproteins. The role of these lipoprotein classes in (1) platelet activation; (2) the intrinsic coagulation cascade, and (3) clot formation and fibrinolysis is discussed.
Copyright 2006 S. Karger AG, Basel.
Similar articles
-
[Thrombin activatable fibrinolysis inhibitor (TAFI) and its importance in the regulation of fibrinolysis].Vnitr Lek. 2004 Jan;50(1):36-44. Vnitr Lek. 2004. PMID: 15015228 Review. Slovak.
-
The influence of the haemodialysis procedure on platelets, coagulation and fibrinolysis.Pathophysiol Haemost Thromb. 2005;34(6):274-8. doi: 10.1159/000093107. Pathophysiol Haemost Thromb. 2005. PMID: 16772739
-
Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.Dan Med Bull. 1993 Sep;40(4):383-408. Dan Med Bull. 1993. PMID: 8222763 Review.
-
[Platelets, coagulation, and fibrinolysis in atherosclerosis formation].Nihon Rinsho. 2011 Jan;69(1):50-4. Nihon Rinsho. 2011. PMID: 21226260 Review. Japanese.
-
[The TAFI system. The new role of fibrinolysis].Hamostaseologie. 2007 Sep;27(4):278-81. Hamostaseologie. 2007. PMID: 17938767 Review. German.
Cited by
-
Emerging Evidence of Pathological Roles of Very-Low-Density Lipoprotein (VLDL).Int J Mol Sci. 2022 Apr 13;23(8):4300. doi: 10.3390/ijms23084300. Int J Mol Sci. 2022. PMID: 35457118 Free PMC article. Review.
-
The Functional Role of Lipoproteins in Atherosclerosis: Novel Directions for Diagnosis and Targeting Therapy.Aging Dis. 2022 Apr 1;13(2):491-520. doi: 10.14336/AD.2021.0929. eCollection 2022 Apr. Aging Dis. 2022. PMID: 35371605 Free PMC article. Review.
-
Platelet function profiles in patients with diabetes mellitus.J Cardiovasc Transl Res. 2013 Jun;6(3):329-45. doi: 10.1007/s12265-013-9449-0. Epub 2013 Feb 13. J Cardiovasc Transl Res. 2013. PMID: 23404189 Review.
-
Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease.Vasc Health Risk Manag. 2016 May 6;12:171-83. doi: 10.2147/VHRM.S104369. eCollection 2016. Vasc Health Risk Manag. 2016. PMID: 27226718 Free PMC article. Review.
-
Reevaluation of the role of HDL in the anticoagulant activated protein C system in humans.J Clin Invest. 2010 May;120(5):1396-9. doi: 10.1172/jci42260. J Clin Invest. 2010. PMID: 20446351 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical